Lifshitz Law Firm Announces Investigation of Navistar International Corporation, Spectrum Pharmaceuticals, Inc., and Tech Data Corporation

NEW YORK, March 22, 2013 /PRNewswire/ --

Navistar International Corporation

Lifshitz Law Firm announces that that a class action suit was filed in the United States District Court for the Northern District of Illinois on behalf of purchasers of Navistar International Corporation ("Navistar" or the "Company") (NAV) between November 3, 2010 and August 1, 2012 ("Class Period").  The Complaint alleges defendants misrepresented and/or failed to disclose that (a) Navistar's attempted methods to achieve compliance with EPA guidelines in truck manufacturing had failed and were not working, and Navistar would be forced to revise its plan to meet guidelines, incurring enormous costs to the Company; (b) Navistar did not have engines ready to meet the 2010 EPA standards; and (c) Navistar's filings with the SEC contained incomplete and misleading disclosures including statements about the costs of recalls and details of various debts.  The firm is investigating legal claims against the officers and Board of Directors of Navistar during the Class Period.

For more information, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: [email protected].

Spectrum Pharmaceuticals, Inc.

Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the District of Nevada, alleging that Spectrum Pharmaceuticals, Inc. ("SPPI" or the "Company") (SPPI) issued false and misleading statements to investors between August 8, 2012 and March 12, 2013 ("Class Period") by failing to adequately disclose material adverse facts in relation to the drug FUSILEV.  The Complaint alleges that defendants failed to disclose that (a) once the availability of the generic drug leucovorin increased, Spectrum's sales of FUSILEV would plummet; and (b) the purported advantages of FUSILEV over leucovorin would not be sufficient for clinics and hospitals to continue to opt for the more expensive FUSILEV once leucovorin was available in larger quantities.  The firm is investigating legal claims against the officers and Board of Directors of SPPI during the Class Period.

For more information, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: [email protected].

Tech Data Corporation

Lifshitz Law Firm announces that it is investigating potential claims against the board of directors of Tech Data Corporation ("Tech Data" or the "Company") (TECD).  On March 21, 2013, The Company reported that its Audit Committee concluded that the Company will restate some or all of its previously issued quarterly and audited annual financial statements for the fiscal years 2011 and 2012, and some or all of the quarters of fiscal year 2013, including the fourth quarter and fiscal year 2013 earnings release dated March 4, 2013. Accordingly, investors should no longer rely upon the Company's previously released financial statements.

For more information, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: [email protected].

Lifshitz Law Firm is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions.  For more information about the firm, please visit our website at www.jlclasslaw.com.

ATTORNEY ADVERTISING. © 2013 Lifshitz Law Firm.  The law firm responsible for this advertisement is Lifshitz Law Firm, 18 East 41^st Street, New York, New York 10017, (212) 213-6222.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law Firm
Phone:   212-213-6222 
Email: [email protected]

SOURCE Lifshitz Law Firm